Purpose: Detection of DNA hypermethylation is emerging as a novel molecular biomarker for different malignancies. We intend to define whether a hypermethylation profile of patients with prostate cancer (PCa) predicts biochemical recurrence (BCR) after radical prostatectomy (RP). Material and Methods: Genome-wide methylation analysis was performed using the GoldenGate Methylation Cancer Panel-I (Illumina, Inc.) on 10 normal prostate tissues and 58 tumor samples from patients treated by RP followed for prostate-specific antigen (PSA) failure (>0.4 ng/ml) and disease progression. Patients were classified on the basis of D'Amico criteria according to clinical staging, PSA at diagnosis and Gleason score after pathologist review. Hypermethylation status of 1505 CpGs present in the promoter region of 807 genes was studied. Hierarchical clustering analysis was performed and relationships with outcome were investigated using log-rank analysis and Cox regression model. Results: We found 28 genes significantly hypermethylated in >20% of the tumors analyzed. Four clusters of patients were characterized by their DNA methylation profile, one at higher risk to develop BCR (p = 0.005). Multivariate analysis revealed patients in this cluster (HR 2.56), and high-risk patients (HR 4.34) according to D'Amico classification were independent predictors of BCR after prostatectomy. From the selected genes MT1A, ALOX12, GSTM2, APC, MYCL2 and RARB hypermethylation predicted BCR and GSTM2 (HR 3.78) and MYCL2 hypermethylation (HR 2.71) did so independently. Conclusion: Epigenetic silencing of GSTM2 and MYCL2 comprise novel molecular markers to predict BCR after surgery for medium- and high-risk localized PCa undergoing surgical treatment and hypermethylation of these genes could be incorporated to the clinical and pathological factors defining the patient at higher risk of PSA failure after prostatectomy. The limitation of the study is that no independent validation cohort is analysed.

Keywords:
DNA methylation, Prostate cancer, Radical prostatectomy, Biochemical recurrence, GSTM2, MYCL2
1.
Center MM, Jemal A, Lortet-Tieulent J, et al: International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-1092.
2.
Punnen S, Cooperberg MR, D'Amico AV, et al: Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013;64:905-915.
3.
Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
4.
Shariat SF, Karakiewicz PI, Suardi N, Kattan MW: Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008;14:4400-4407.
5.
Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML: Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008;179:1354-1360; discussion 1360-1361.
6.
Valdés-Mora F, Clark SJ: Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene 2015;34:1609-1618.
7.
Ashour N, Angulo JC, Andrés G, et al: A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate 2014;74:1171-1182.
8.
Angulo JC, Andrés G, Ashour N, Sánchez-Chapado M, López JI, Ropero S: Development of castration resistant prostate cancer can be predicted by a DNA hypermethylation profile. J Urol 2016;195:619-626.
9.
Bastian PJ, Palapattu GS, Lin X, et al: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-4043.
10.
Haldrup C, Mundbjerg K, Vestergaard EM, et al: DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013;31:3250-3258.
11.
Rosenbaum E, Hoque MO, Cohen Y, et al: Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-8325.
12.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
13.
Joniau S, Tosco L, Briganti A, et al; European Multicenter Prostate Cancer Clinical and Translational Research Group: Results of surgery for high-risk prostate cancer. Curr Opin Urol 2013;23:342-348.
14.
Albany C, Alva AS, Aparicio AM, et al: Epigenetics in prostate cancer. Prostate Cancer 2011;2011:580318.
15.
Strand SH, Orntoft TF, Sorensen KD: Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014;15:16544-16576.
16.
Maldonado L, Brait M, Loyo M, et al: GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol 2014;192:1542-1548.
17.
Rosenbaum E, Begum S, Brait M, et al: AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate 2012;72:1133-1139.
18.
Dietrich D, Hasinger O, Bañez LL, et al: Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn 2013;15:270-279.
19.
Kristensen H, Haldrup C, Strand S, et al: Hypermethylation of the GABRE∼miR-452∼miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res 2014;20:2169-2181.
20.
Stott-Miller M, Zhao S, Wright JL, et al: Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2014;23:1331-1339.
21.
Wang L, Xie PG, Lin YL, Ma JG, Li WP: Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy. Med Sci Monit 2014;20:1363-1368.
22.
Litovkin K, Joniau S, Lerut E, et al: Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol 2014;140:1849-1861.
23.
Litovkin K, Van Eynde A, Joniau S, et al: DNA methylation-guided prediction of clinical failure in high-risk prostate cancer. PLoS One 2015;10:e0130651.
24.
Horning AM, Awe JA, Wang CM, et al: DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. Prostate 2015;75:1790-1801.
25.
Vasiljević N, Ahmad AS, Beesley C, et al: Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis 2013;16:35-40.
26.
Daniunaite K, Jarmalaite S, Kalinauskaite N, et al: Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol 2014;192:1849-1855.
27.
Chen R, Ren S, Meng T, Aguilar J, Sun Y: Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis. PLoS One 2013;8:e74775.
28.
Norrgård MA, Hellman U, Mannervik B: Cys-X scanning for expansion of active-site residues and modulation of catalytic functions in a glutathione transferase. J Biol Chem 2011;286:16871-16888.
29.
Robertson NG, Pomponio RJ, Mutter GL, Morton CC: Testis-specific expression of the human MYCL2 gene. Nucleic Acids Res 1991;19:3129-3137.
30.
Darr OA, Colacino JA, Tang AL, et al: Epigenetic alterations in metastatic cutaneous carcinoma. Head Neck 2015;37:994-1001.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.